STOCK TITAN

[Form 4] Shenandoah Telecom Co Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

On 07/01/2025, Fennec Pharmaceuticals Inc. (FENC) filed a Form 4 reporting that Chief Financial Officer Robert Andrade acquired 2,431 common shares on 06/30/2025.

The acquisition reflects the release of restrictions on equity awards originally granted on 03/31/2023 and 05/16/2024. Because the shares vested at a price of $0, the event represents routine compensation vesting rather than an open-market purchase or sale.

After the transaction, Andrade directly holds 163,382 FENC common shares. No derivative security activity was disclosed.

This filing signals a modest increase in the executive’s unrestricted stake and indicates continued alignment with shareholder interests, but the size of the release is unlikely to have a material impact on the company’s valuation or trading dynamics.

Il 07/01/2025, Fennec Pharmaceuticals Inc. (FENC) ha presentato un Modulo 4 segnalando che il Direttore Finanziario Robert Andrade ha acquisito 2.431 azioni ordinarie il 30/06/2025.

L'acquisizione riflette la cessazione delle restrizioni su premi azionari originariamente concessi il 31/03/2023 e il 16/05/2024. Poiché le azioni sono state maturate a un prezzo di $0, l'evento rappresenta una normale maturazione di compensi e non un acquisto o vendita sul mercato aperto.

Dopo la transazione, Andrade detiene direttamente 163.382 azioni ordinarie FENC. Non sono state divulgate attività relative a titoli derivati.

Questa comunicazione segnala un modesto aumento della quota non vincolata dell'esecutivo e indica un continuo allineamento con gli interessi degli azionisti, ma la dimensione della liberazione è improbabile che abbia un impatto significativo sulla valutazione o sulle dinamiche di mercato della società.

El 07/01/2025, Fennec Pharmaceuticals Inc. (FENC) presentó un Formulario 4 informando que el Director Financiero Robert Andrade adquirió 2,431 acciones comunes el 30/06/2025.

La adquisición refleja la liberación de restricciones sobre premios de acciones otorgados originalmente el 31/03/2023 y el 16/05/2024. Dado que las acciones se consolidaron a un precio de $0, el evento representa una consolidación rutinaria de compensación y no una compra o venta en el mercado abierto.

Después de la transacción, Andrade posee directamente 163,382 acciones comunes de FENC. No se divulgaron actividades relacionadas con valores derivados.

Esta presentación señala un aumento modesto en la participación sin restricciones del ejecutivo e indica una continua alineación con los intereses de los accionistas, pero es poco probable que el tamaño de la liberación tenga un impacto material en la valoración o dinámica de negociación de la empresa.

2025년 1월 7일, Fennec Pharmaceuticals Inc.(FENC)는 최고재무책임자 로버트 안드라데가 2025년 6월 30일에 2,431 보통주를 취득했다고 Form 4를 제출했습니다.

이번 취득은 2023년 3월 31일과 2024년 5월 16일에 원래 부여된 주식 보상의 제한 해제를 반영합니다. 주식이 $0의 가격으로 취득되었기 때문에 이 사건은 공개 시장에서의 매매가 아닌 정기 보상 취득에 해당합니다.

거래 후 안드라데는 직접 163,382 FENC 보통주를 보유하게 되었습니다. 파생 증권 관련 활동은 공개되지 않았습니다.

이번 제출은 경영진의 제한 없는 지분이 소폭 증가했음을 나타내며 주주 이익과의 지속적인 일치를 보여주지만, 해제 규모가 회사의 가치 평가나 거래 동향에 중대한 영향을 미칠 가능성은 낮습니다.

Le 07/01/2025, Fennec Pharmaceuticals Inc. (FENC) a déposé un formulaire 4 indiquant que le Directeur financier Robert Andrade a acquis 2 431 actions ordinaires le 30/06/2025.

L'acquisition reflète la levée des restrictions sur des attributions d'actions initialement accordées le 31/03/2023 et le 16/05/2024. Comme les actions ont été acquises à un prix de 0 $, cet événement représente une acquisition de rémunération habituelle plutôt qu'un achat ou une vente sur le marché libre.

Après la transaction, Andrade détient directement 163 382 actions ordinaires FENC. Aucune activité liée à des titres dérivés n'a été divulguée.

Ce dépôt signale une légère augmentation de la participation libre de l'exécutif et indique un alignement continu avec les intérêts des actionnaires, mais l'ampleur de cette levée est peu susceptible d'avoir un impact significatif sur la valorisation ou la dynamique de négociation de l'entreprise.

Am 07.01.2025 reichte Fennec Pharmaceuticals Inc. (FENC) ein Formular 4 ein, in dem berichtet wurde, dass Finanzvorstand Robert Andrade am 30.06.2025 2.431 Stammaktien erworben hat.

Der Erwerb spiegelt die Aufhebung von Beschränkungen bei Aktienprämien wider, die ursprünglich am 31.03.2023 und 16.05.2024 gewährt wurden. Da die Aktien zu einem Preis von $0 erworben wurden, handelt es sich bei dem Ereignis um eine routinemäßige Vergütungsfreigabe und nicht um einen Kauf oder Verkauf am offenen Markt.

Nach der Transaktion hält Andrade direkt 163.382 FENC-Stammaktien. Es wurden keine Aktivitäten im Zusammenhang mit Derivaten gemeldet.

Diese Meldung signalisiert eine moderate Erhöhung des uneingeschränkten Anteils des Geschäftsführers und zeigt eine fortgesetzte Ausrichtung an den Interessen der Aktionäre, jedoch ist es unwahrscheinlich, dass die Größenordnung der Freigabe einen wesentlichen Einfluss auf die Bewertung oder den Handelsverlauf des Unternehmens hat.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting; CFO now owns 163,382 shares—neutral impact.

The Form 4 shows Robert Andrade received 2,431 common shares when restrictions lapsed on prior equity grants. With no cash outlay or market transaction, the event is administrative. Andrade’s direct ownership rises modestly, reinforcing insider alignment but not altering Fennec’s capital structure or signaling new information about fundamentals. I therefore view the disclosure as non-impactful for investors.

Il 07/01/2025, Fennec Pharmaceuticals Inc. (FENC) ha presentato un Modulo 4 segnalando che il Direttore Finanziario Robert Andrade ha acquisito 2.431 azioni ordinarie il 30/06/2025.

L'acquisizione riflette la cessazione delle restrizioni su premi azionari originariamente concessi il 31/03/2023 e il 16/05/2024. Poiché le azioni sono state maturate a un prezzo di $0, l'evento rappresenta una normale maturazione di compensi e non un acquisto o vendita sul mercato aperto.

Dopo la transazione, Andrade detiene direttamente 163.382 azioni ordinarie FENC. Non sono state divulgate attività relative a titoli derivati.

Questa comunicazione segnala un modesto aumento della quota non vincolata dell'esecutivo e indica un continuo allineamento con gli interessi degli azionisti, ma la dimensione della liberazione è improbabile che abbia un impatto significativo sulla valutazione o sulle dinamiche di mercato della società.

El 07/01/2025, Fennec Pharmaceuticals Inc. (FENC) presentó un Formulario 4 informando que el Director Financiero Robert Andrade adquirió 2,431 acciones comunes el 30/06/2025.

La adquisición refleja la liberación de restricciones sobre premios de acciones otorgados originalmente el 31/03/2023 y el 16/05/2024. Dado que las acciones se consolidaron a un precio de $0, el evento representa una consolidación rutinaria de compensación y no una compra o venta en el mercado abierto.

Después de la transacción, Andrade posee directamente 163,382 acciones comunes de FENC. No se divulgaron actividades relacionadas con valores derivados.

Esta presentación señala un aumento modesto en la participación sin restricciones del ejecutivo e indica una continua alineación con los intereses de los accionistas, pero es poco probable que el tamaño de la liberación tenga un impacto material en la valoración o dinámica de negociación de la empresa.

2025년 1월 7일, Fennec Pharmaceuticals Inc.(FENC)는 최고재무책임자 로버트 안드라데가 2025년 6월 30일에 2,431 보통주를 취득했다고 Form 4를 제출했습니다.

이번 취득은 2023년 3월 31일과 2024년 5월 16일에 원래 부여된 주식 보상의 제한 해제를 반영합니다. 주식이 $0의 가격으로 취득되었기 때문에 이 사건은 공개 시장에서의 매매가 아닌 정기 보상 취득에 해당합니다.

거래 후 안드라데는 직접 163,382 FENC 보통주를 보유하게 되었습니다. 파생 증권 관련 활동은 공개되지 않았습니다.

이번 제출은 경영진의 제한 없는 지분이 소폭 증가했음을 나타내며 주주 이익과의 지속적인 일치를 보여주지만, 해제 규모가 회사의 가치 평가나 거래 동향에 중대한 영향을 미칠 가능성은 낮습니다.

Le 07/01/2025, Fennec Pharmaceuticals Inc. (FENC) a déposé un formulaire 4 indiquant que le Directeur financier Robert Andrade a acquis 2 431 actions ordinaires le 30/06/2025.

L'acquisition reflète la levée des restrictions sur des attributions d'actions initialement accordées le 31/03/2023 et le 16/05/2024. Comme les actions ont été acquises à un prix de 0 $, cet événement représente une acquisition de rémunération habituelle plutôt qu'un achat ou une vente sur le marché libre.

Après la transaction, Andrade détient directement 163 382 actions ordinaires FENC. Aucune activité liée à des titres dérivés n'a été divulguée.

Ce dépôt signale une légère augmentation de la participation libre de l'exécutif et indique un alignement continu avec les intérêts des actionnaires, mais l'ampleur de cette levée est peu susceptible d'avoir un impact significatif sur la valorisation ou la dynamique de négociation de l'entreprise.

Am 07.01.2025 reichte Fennec Pharmaceuticals Inc. (FENC) ein Formular 4 ein, in dem berichtet wurde, dass Finanzvorstand Robert Andrade am 30.06.2025 2.431 Stammaktien erworben hat.

Der Erwerb spiegelt die Aufhebung von Beschränkungen bei Aktienprämien wider, die ursprünglich am 31.03.2023 und 16.05.2024 gewährt wurden. Da die Aktien zu einem Preis von $0 erworben wurden, handelt es sich bei dem Ereignis um eine routinemäßige Vergütungsfreigabe und nicht um einen Kauf oder Verkauf am offenen Markt.

Nach der Transaktion hält Andrade direkt 163.382 FENC-Stammaktien. Es wurden keine Aktivitäten im Zusammenhang mit Derivaten gemeldet.

Diese Meldung signalisiert eine moderate Erhöhung des uneingeschränkten Anteils des Geschäftsführers und zeigt eine fortgesetzte Ausrichtung an den Interessen der Aktionäre, jedoch ist es unwahrscheinlich, dass die Größenordnung der Freigabe einen wesentlichen Einfluss auf die Bewertung oder den Handelsverlauf des Unternehmens hat.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Beckett Thomas

(Last) (First) (Middle)
PO BOX 459

(Street)
EDINBURG VA 22824

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SHENANDOAH TELECOMMUNICATIONS CO/VA/ [ SHEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common 07/01/2025 A(1) 29.2826 A $13.66 22,652.3223 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares received in lieu of director fees.
/s/ Christopher E French Attorney in Fact for Thomas Beckett 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Shenandoah Telecommunications

NASDAQ:SHEN

SHEN Rankings

SHEN Latest News

SHEN Latest SEC Filings

SHEN Stock Data

769.65M
49.67M
4.46%
67.48%
3.97%
Telecom Services
Telephone Communications (no Radiotelephone)
Link
United States
EDINBURG